AR111830A1 - Anticuerpos monoclonales antagonistas contra cd40 y sus usos - Google Patents

Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Info

Publication number
AR111830A1
AR111830A1 ARP180101388A ARP180101388A AR111830A1 AR 111830 A1 AR111830 A1 AR 111830A1 AR P180101388 A ARP180101388 A AR P180101388A AR P180101388 A ARP180101388 A AR P180101388A AR 111830 A1 AR111830 A1 AR 111830A1
Authority
AR
Argentina
Prior art keywords
antibody
seq
antigen binding
binding portion
human
Prior art date
Application number
ARP180101388A
Other languages
English (en)
Inventor
Suzanne J Suchard
Mary Struthers
Aaron Yamniuk
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR111830A1 publication Critical patent/AR111830A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La descripción proporciona anticuerpos que se fijan a CD40, que incluye un anticuerpo humanizado y un anticuerpo quimérico con dominios Fc diferentes. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de IgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. Composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluye la actividad de CD40. Reivindicación 1: Un anticuerpo aislado, o una porción de fijación al antígeno de este, que se fija específicamente a CD40 humana, en donde dicho anticuerpo comprende una cadena pesada y una cadena liviana, caracterizado porque: dicha cadena pesada comprende una CDR1 que comprende GYTFTDLSMHW (SEQ ID Nº 1), una CDR2 que comprende YITPSSGYTAYNQKFKG (SEQ ID Nº 2), una CDR3 que comprende LILQRGAY (SEQ ID Nº 3) y una región constante de la cadena pesada humana; y dicha cadena liviana comprende una CDR1 que comprende RASKNVDSYGNSFMHW (SEQ ID Nº 4), una CDR2 que comprende RASNLES (SEQ ID Nº 5), y una CDR3 que comprende QQSNEDPLT (SEQ ID Nº 6) y una región constante de la cadena liviana humana; y dicha región constante de la cadena pesada humana es un dominio Fc de IgG1 humana que comprende (1) una mutación en la posición 238 Kabat que reduce la fijación a los receptores Fc g (FcgR), en donde prolina 238 (P238) se muta a uno de los residuos seleccionados del grupo que consiste en lisina, serina, alanina, arginina y triptófano, y en donde el anticuerpo, o una porción de fijación al antígeno de este, tiene una fijación a FcgR reducida; o (2) una alanina sustituida en la posición 297 Kabat. Reivindicación 16: Un ácido nucleico caracterizado porque codifica un anticuerpo aislado, o una porción de fijación al antígeno de este, de acuerdo con cualquiera de las reivindicaciones 1 a 15. Reivindicación 17: Un vector de expresión caracterizado porque comprende la molécula del ácido nucleico de acuerdo con la reivindicación 16. Reivindicación 18: Una célula caracterizada porque está transformada con un vector de expresión de acuerdo con la reivindicación 17. Reivindicación 19: Un método para preparar un anticuerpo anti-CD40 humana, o una porción de fijación al antígeno de este, caracterizado porque comprende: a) expresar el anticuerpo, o la porción de fijación al antígeno de este, en la célula de acuerdo con la reivindicación 18; y b) aislar el anticuerpo, o una porción de fijación al antígeno de este, de la célula.
ARP180101388A 2017-05-25 2018-05-24 Anticuerpos monoclonales antagonistas contra cd40 y sus usos AR111830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511079P 2017-05-25 2017-05-25

Publications (1)

Publication Number Publication Date
AR111830A1 true AR111830A1 (es) 2019-08-21

Family

ID=62567875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101388A AR111830A1 (es) 2017-05-25 2018-05-24 Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Country Status (9)

Country Link
US (3) US11220550B2 (es)
EP (1) EP3630831B1 (es)
JP (1) JP7257335B2 (es)
KR (1) KR20200011937A (es)
CN (1) CN110621697B (es)
AR (1) AR111830A1 (es)
ES (1) ES2923143T3 (es)
TW (1) TW201902934A (es)
WO (1) WO2018217976A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
ES2963807T3 (es) 2016-06-08 2024-04-02 Xencor Inc Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
ES2923143T3 (es) 2017-05-25 2022-09-23 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra CD40 y sus usos
CN116333129A (zh) * 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
US20200148779A1 (en) * 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CA3159486A1 (en) 2019-12-19 2021-06-24 Thomas M. Lancaster Ultra-long acting insulin-fc fusion proteins and methods of use
EP4153630A1 (en) 2020-05-18 2023-03-29 Bristol-Myers Squibb Company Antibody variants with improved pharmacokinetic properties
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB2353887B (en) 1999-09-04 2003-09-24 Ibm Speech recognition system
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20150315284A1 (en) 2004-11-09 2015-11-05 Xencor, Inc. OPTIMIZED Fc VARIANTS
JP2009511067A (ja) 2005-10-14 2009-03-19 メディミューン，エルエルシー 抗体ライブラリーの細胞提示
AU2008207898B2 (en) 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
DK2155789T3 (da) 2007-05-01 2013-10-21 Res Dev Foundation Immunoglobulin-Fc-biblioteker
NZ586053A (en) 2007-11-09 2012-09-28 Peregrine Pharmaceuticals Inc Anti-vegf antibody compositions and methods
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PT3178851T (pt) 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
WO2012046745A1 (ja) 2010-10-04 2012-04-12 独立行政法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012088461A2 (en) * 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
KR101734614B1 (ko) 2011-04-21 2017-05-12 브리스톨-마이어스 스큅 컴퍼니 Cd40을 길항하는 항체 폴리펩티드
CN108144058A (zh) * 2011-09-30 2018-06-12 中外制药株式会社 促进抗原消除的抗原结合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
PE20211533A1 (es) * 2014-08-04 2021-08-16 Hoffmann La Roche Moleculas biespecificas de unon a antigeno activadoras de celulas t
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
CN106687135A (zh) * 2014-09-15 2017-05-17 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3303395B1 (en) 2015-05-29 2019-12-11 AbbVie Inc. Anti-cd40 antibodies and uses thereof
JP7350467B2 (ja) 2015-06-29 2023-09-26 ブリストル－マイヤーズ スクイブ カンパニー Ｃｄ４０に対する抗体
BR112017028353A2 (pt) * 2015-06-29 2018-09-04 The Rockfeller University anticorpos para cd40 com atividade agonista melhorada
US20190048089A1 (en) 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
EP3523329A1 (en) 2016-10-06 2019-08-14 GlaxoSmithKline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
US11603406B2 (en) 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
US20200095323A1 (en) 2017-03-20 2020-03-26 The General Hospital Corporation MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
CN116333129A (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
ES2923143T3 (es) 2017-05-25 2022-09-23 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra CD40 y sus usos
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions

Also Published As

Publication number Publication date
TW201902934A (zh) 2019-01-16
JP2020521453A (ja) 2020-07-27
ES2923143T3 (es) 2022-09-23
US11220550B2 (en) 2022-01-11
EP3630831B1 (en) 2022-06-15
EP3630831A1 (en) 2020-04-08
US20180340031A1 (en) 2018-11-29
JP7257335B2 (ja) 2023-04-13
US11613585B2 (en) 2023-03-28
WO2018217976A1 (en) 2018-11-29
US20230322941A1 (en) 2023-10-12
KR20200011937A (ko) 2020-02-04
CN110621697B (zh) 2023-06-27
US20220177596A1 (en) 2022-06-09
CN110621697A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
AR111830A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7158552B2 (ja) 抗Ｔｉｍ－３抗体及びその使用
JP7345578B2 (ja) 新規抗ｐｄ－ｌ１抗体
KR102372274B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
CN109843923B (zh) 针对ctla-4的单结构域抗体及其变体
DK2976361T3 (en) HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2018520657A5 (es)
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
JP2017532037A (ja) ヒト化抗ｏｘ４０抗体及びその使用
JP2022501377A (ja) 血液悪性腫瘍の処置において使用するための新規の二重特異性抗体
AR103442A1 (es) Anticuerpos y receptores de antígenos quiméricos específicos de ror1
AR095115A1 (es) Anticuerpos que comprenden dominios constantes quiméricos
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
RU2012142231A (ru) Антитела против csf-1r человека и их применение
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
US20220162320A1 (en) Multispecific binding proteins
AR117091A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
KR20200120641A (ko) Pd-1에 대한 단일-도메인 항체 및 이의 변이체
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
JP2022512875A (ja) 抗体製剤
EP4271484A1 (en) Antibodies to tnfr2 and uses thereof
WO2023045606A1 (zh) 抗tnfr2单克隆抗体及其应用
AR115014A1 (es) Anticuerpos contra mica y/o micb y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure